Toll Brothers Likely To Report Lower Q2 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Toll Brothers Likely To Report Lower Q2 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Toll Brothers Likely To Report Lower Q2 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Toll Brothers Likely To Report Lower Q2 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Toll Brothers Likely To Report Lower Q2 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Turkish Lira Plummets To Record Low Vs. Euro On Policy Fears

Options Corner: Redfin's Value Compression Sets The Stage For A Bullish Bounce Back

Investors Piled Into Long-Term Treasury ETFs Ahead Of Moody's Downgrade: Will Confidence Hold?

Intuit Q3 Preview: 'Price-Disruptor' Drives Adoption, Analyst Expects Revenue Beat

Snowflake Eyes Q1 Momentum As AI Partnerships Stack Up: Goldman Sachs

Strategy's Options: A Look at What the Big Money is Thinking

Strategy's Options: A Look at What the Big Money is Thinking

Strategy's Options: A Look at What the Big Money is Thinking

US Stocks Likely To Open Lower After Moody's Downgrade: 'Bear Market Isn't Fully Recovered Yet, But It Is Close,' Says Expert

Unibail-Rodamco upgraded to Equal Weight from Underweight at Morgan Stanley

BP downgraded to Hold from Buy at Jefferies

Cingulate price target lowered to $11 from $12 at Roth Capital

AdvanSix upgraded to Overweight from Neutral at Piper Sandler

Methanex upgraded to Overweight from Neutral at Piper Sandler

Inozyme downgraded to Hold from Buy at TD Cowen

Inozyme downgraded to Neutral from Overweight at Piper Sandler

TD remains confident in approval after UroGen briefing docs

Analyst Lowers Target Q1 Forecast Amid Spending Slump, Rising Consumer Tariffs

This HNI Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Friday

This HNI Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Friday

These Analysts Cut Their Forecasts On Alibaba After Q4 Results

Trip.com Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Trip.com Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Trip.com Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Trip.com Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

These Analysts Revise Their Forecasts On Advanced Drainage Systems After Q4 Earnings

These Analysts Revise Their Forecasts On Advanced Drainage Systems After Q4 Earnings

These Analysts Revise Their Forecasts On Advanced Drainage Systems After Q4 Earnings

Deere's Resilience Shines Through Tariffs, Analysts Raise Price Forecasts

Inozyme downgraded to Hold from Buy at Jefferies

Acadia Nuplazid patent ruling removes 'key overhang,' says BMO Capital

Acadia Pharmaceuticals price target raised to $19 from $17 at Oppenheimer

Acadia Pharmaceuticals price target raised to $30 from $27 at Needham

Archer Aviation (ACHR) Stock Soars On LA28 Olympics Deal, Strong Earnings

Archer Aviation (ACHR) Stock Soars On LA28 Olympics Deal, Strong Earnings

Inozyme downgraded to Market Perform from Outperform at Raymond James

Watches of Switzerland price target raised to 525 GBp from 520 GBp at Barclays

National Grid price target raised to 1,250 GBp from 1,145 GBp at Barclays

Atresmedia price target raised to EUR 5 from EUR 4.50 at Barclays

Siemens price target raised to EUR 260 from EUR 245 at Citi

Daimler Truck price target raised to EUR 45 from EUR 39.80 at Citi

Allianz price target raised to EUR 349 from EUR 341 at Citi

Inozyme downgraded to Hold from Buy at Needham

Terna price target raised to EUR 8.20 from EUR 8 at Morgan Stanley

Siemens price target raised to EUR 230 from EUR 215 at Morgan Stanley

Metlen Energy price target raised to EUR 62 from EUR 48 at Morgan Stanley

Stantec price target raised to C$165 from C$145 at TD Securities

Keyera price target raised to C$47 from C$45 at TD Securities

InterRent REIT price target raised to C$13.50 from C$13 at TD Securities

AtkinsRealis price target raised to C$106 from C$95 at TD Securities

Vecima Networks price target lowered to C$18 from C$20 at Raymond James

Superior Plus price target raised to C$10.50 from C$9.50 at Raymond James

Quarterhill price target lowered to C$2 from C$2.25 at Raymond James

Nexus Industrial price target raised to C$8.50 from C$8.25 at Raymond James

Keyera price target raised to C$51 from C$50 at Raymond James

AtkinsRealis price target raised to C$110 from C$105 at Raymond James

Stantec price target raised to C$150 from C$138 at RBC Capital

Sienna Senior Living price target raised to C$19 from C$18 at RBC Capital

AtkinsRealis price target raised to C$102 from C$92 at RBC Capital

ARC Resources price target raised to C$34 from C$32 at RBC Capital

H&R REIT price target raised to C$11.50 from C$11 at BMO Capital

Nexus Industrial price target raised to C$7.25 from C$6.75 at National Bank

Keyera price target raised to C$43 from C$41 at National Bank

ARC Resources price target raised to C$35 from C$33 at National Bank

Camping World price target raised to $21 from $16 at Citi

Laurentian Bank price target lowered to C$25 from C$27 at National Bank

Foot Locker price target raised to $24 from $20 at Telsey Advisory

Keyera price target raised to C$51 from C$50 at Scotiabank

Western Digital price target raised to $62 from $38 at BNP Paribas Exane

Zoom Communications price target raised to $85 from $75 at Scotiabank

Inozyme downgraded to Neutral from Outperform at Wedbush

Cisco downgraded to Neutral from Buy at New Street

Vista Energy price target lowered to $57 from $64 at UBS

Advanced Drainage price target lowered to $146 from $155 at UBS

Charter upgraded to Outperform from Perform at Oppenheimer

Intuit price target raised to $720 from $655 at UBS

Informatica price target raised to $21 from $20 at UBS

Millicom price target raised to $39.50 from $31.50 at UBS

Take-Two price target raised to $275 from $230 at UBS

Marriott price target lowered to $280 from $285 at Susquehanna

Choice Hotels price target lowered to $140 from $155 at Susquehanna

Astera Labs initiated with a Neutral at Susquehanna

Permian Resources price target raised to $17 from $16 at RBC Capital

Eton Pharmaceuticals price target raised to $26 from $24 at B. Riley

Customers Bancorp price target raised to $82 from $81 at B. Riley

Bitcoin Depot price target raised to $5.50 from $4.70 at B. Riley

Take-Two price target raised to $269 from $253 at Wedbush

Angel Oak Mortgage REIT price target raised to $13 from $12 at B. Riley

Rocket Pharmaceuticals price target raised to $30 from $20 at Cantor Fitzgerald

Baker Hughes price target lowered to $45 from $55 at Morgan Stanley

Take-Two price target raised to $250 from $240 at Raymond James

Karooooo price target raised to $58 from $51 at Raymond James

Doximity price target lowered to $65 from $83 at Raymond James

Array Technologies price target raised to $12 from $10 at Guggenheim

Cidara Therapeutics price target raised to $50 from $35 at Guggenheim